Antiviral Resistance against Viral Mutation: Praxis and Policy for SARS CoV-2
AbstractNew tools developed by Moderna, BioNTech/Pfizer and Oxford/Astrazeneca provide universal solutions to previously problematic aspects of drug or vaccine delivery, uptake and toxicity, portending new tools across the medical sciences. A novel method is presented based on estimating protein backbone free energy via geometry to predict effective antiviral targets, antigens and vaccine cargoes that are resistant to viral mutation. This method, partly described in earlier work of the author, is reviewed and reformulated here in light of the profusion of recent structural data on the SARS CoV-2 spike glycoprotein and its latest mutations. Scientific and regulatory challenges to nucleic acid therapeutic and vaccine development and deployment are also discussed.